MedPath

A Clinical Study to Evaluate the Efficacy and Safety of OLNP-06 versus Placebo in Subjects with Primary Dysmenorrhea

Not Applicable
Conditions
Health Condition 1: K928- Other specified diseases of the digestive system
Registration Number
CTRI/2022/02/039897
Lead Sponsor
Olene Life Sciences Private Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Healthy Female subjects 18 â?? 35 years of age

Regular menstrual cycle between 21 - 35 days with bleeding duration between three to seven days

Suffering from primary dysmenorrhea

Suffering from menstrual pain within the recent three consecutive months with a maximum VAS score of >=4

Willing to sign the informed consent and comply with study procedure

Exclusion Criteria

Diagnosis of secondary dysmenorrhea due to pelvic pathology, such as uterine fibroids, adenomyosis, endometriosis, or pelvic inflammatory diseases

Female who is lactating, currently pregnant, intention to become pregnant.

Current intrauterine device.

Patient taking regular NSAIDs for some therapeutic indication for pain relief other than menstrual pain.

Evidence or history of clinically significant (in the judgment of the Investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, or malignancies.

History of psychiatric disorder that may impair the ability of subjects to provide written informed consent

Metrorrhagia with menstrual cycles less than 21 days or oligomenorrhea with cycles over 40 days.

Oral contraceptives or other hormonal treatment use within the past three months.

Subject who is having allergic to ginger.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mean Change from baseline in <br/ ><br>Maximum Dysmenorrheic Pain VAS Score <br/ ><br>Timepoint: Day 0, Week 4, week 8 <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Mean Change from baseline to end of trial in <br/ ><br>oVMS <br/ ><br>oSymptoms reported during menstruation (Low back pain, fatigue, nausea, headache, diarrhea, vomiting) <br/ ><br>Timepoint: Day 0, Day 28, Day 56
© Copyright 2025. All Rights Reserved by MedPath